Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 26.86 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - aclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. aclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of aclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae , haemophilus influenzae , staphylococci, and streptococcus pyogenes   lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae , haemophilus influenzae, and streptococcus pyogenes   pharyngitis and tonsillitis , caused by streptococcus pyogenes   note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections , including pyelonephritis and cystitis, caused by escherichia coli, proteus mirabilis, klebsiella spp., and coagulase-negative staphy

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae, staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis, caused by streptococcus pyogenes note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclo

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefaclor monohydrate 267.5mg equivalent to cefaclor 250 mg (plus 2% overage);  ; cefaclor monohydrate 267.5mg equivalent to cefaclor 250 mg (plus 2% overage) - capsule - 250 mg - active: cefaclor monohydrate 267.5mg equivalent to cefaclor 250 mg (plus 2% overage)   excipient: brilliant blue fcf carmoisine colloidal silicon dioxide croscarmellose sodium gelatin   magnesium stearate methyl hydroxybenzoate   ponceau 4r pregelatinised maize starch propyl hydroxybenzoate   titanium dioxide   water   active: cefaclor monohydrate 267.5mg equivalent to cefaclor 250 mg (plus 2% overage) excipient: brilliant blue fcf carmoisine colloidal silicon dioxide croscarmellose sodium gelatin   magnesium stearate methyl hydroxybenzoate   ponceau 4r pregelatinised maize starch propyl hydroxybenzoate   titanium dioxide   - · lower respiratory infections, including pneumonia caused by s. pneumoniae, h. influenzae (including both ampicillin-sensitive and ampicillin-resistant strains), and s. pyogenes (group a beta- haemolytic streptococci), m.catarrhalis, acute bronchitis, and acute exacerbations of chronic bronchitis. · upper respiratory infections, including pharyngitis and tonsillitis caused by s. pyogenes (group a beta-haemolytic streptococci) and m. catarrhalis. note: penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. amoxicillin has been recommended by the american heart association as the standard regimen for the prophylaxis of bacterial endocarditis for dental, oral, and upper respiratory tract procedures, with penicillin v a rational and acceptable alternative in the prophylaxis against beta-haemolytic streptococcal bacteriaemia in this setting. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever or bacterial endocarditis are not available at present.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefaclor monohydrate 55.6 mg/ml equivalent to cefaclor 50 mg/ml - granules for oral suspension - 250 mg/5ml - active: cefaclor monohydrate 55.6 mg/ml equivalent to cefaclor 50 mg/ml excipient: allura red ac citric acid colloidal silicon dioxide simeticone sodium benzoate sodium citrate dihydrate strawberry flavour 052311 ap0551 sucrose xanthan gum

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate -

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - cefaclor monohydrate 52.45 mg/ml equivalent to cefaclor 50 mg/ml (with 2.5% overage) - granules for oral suspension - 250 mg/5ml - active: cefaclor monohydrate 52.45 mg/ml equivalent to cefaclor 50 mg/ml (with 2.5% overage) excipient: dimeticone iron oxide yellow maize starch methylcellulose sodium laurilsulfate strawberry flavour 052312 ap0551 sucrose xanthan gum

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - cefaclor monohydrate - oral capsule - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - cefaclor monohydrate - oral capsule - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - cefaclor monohydrate - oral capsule - 250mg